SIXL - ETF AI Analysis
Top Page
ETC 6 Meridian Low Beta Equity ETF (SIXL)
SIXL, the ETC 6 Meridian Low Beta Equity ETF, earns a solid overall rating thanks to several high-quality holdings like Dynatrace and Qualys, which bring strong financial performance, robust revenue growth, and positive earnings outlooks that support the fund’s long-term potential. The rating is held back somewhat by names such as CVR Energy and International Seaways, where leverage, cash flow challenges, and revenue declines introduce more uncertainty. A key risk factor is the fund’s exposure to companies with high valuations and some bearish technical signals, which could increase volatility if market conditions worsen.
SIXL vs. SPDR S&P 500 ETF (SPY)
- AUM
- 208.41M
- Region
- North America
- Expense Ratio
- 0.46%
- Beta
- 0.29
- Issuer
- Meridian
- Inception Date
- May 11, 2020
- Dividend Yield
- 2.11%
- Asset Class
- Equity
- Index Tracked
- No Underlying Index
SIXL Summary
The ETC 6 Meridian Low Beta Equity ETF (SIXL) is a U.S. stock fund that aims to give you broad market exposure while focusing on companies that tend to move less than the overall market. It doesn’t track a single index, but it follows a “low volatility” theme and spreads investments across many sectors like utilities, consumer defensive, financials, and health care. Well-known holdings include CVS Health and DaVita. Someone might invest for steadier, long-term growth and diversification. A key risk is that the fund can still lose value and may lag the market in strong bull markets.
How much will it cost me?
This ETF has an expense ratio of 0.46%, which means you’ll pay about $4.60 per year for every $1,000 you invest. That’s higher than the average low-cost index ETF because SIXL is actively managed and uses a specialized low-beta strategy to try to reduce volatility.
What would affect this ETF?
SIXL could benefit if the U.S. economy grows steadily while volatility stays moderate, since its focus on low-beta stocks and defensive sectors like consumer staples, utilities, and health care is designed to provide more stable returns, and strong performance in energy and technology names such as Marathon Petroleum and Dynatrace could also help. On the other hand, sharp market rallies led by high-risk growth stocks, rising interest rates that pressure financials and real estate, or regulatory and business setbacks for its specialized holdings in health care and energy could weigh on future performance.
SIXL Top 10 Holdings
SIXL leans into a defensive, low-volatility story, with steady names like Philip Morris and AbbVie helping anchor returns while not exactly lighting up the scoreboard. The real spark comes from rising tech and health-care picks such as Dynatrace, Qualys, and Haemonetics, which have been quietly powering performance in the background. On the flip side, Kroger has been lagging and occasionally acts like a small brake on the fund’s momentum. Overall, the ETF is U.S.-focused and tilted toward stable, defensive sectors with a dash of growth-oriented tech.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 PCRX | Pacira Pharmaceuticals | 0.56% | $1.16M | $1.45B | 68.14% | 69Neutral |
 CVI | CVR Energy | 0.52% | $1.08M | $5.85B | 48.56% | 60Neutral |
 OPCH | Option Care Health | 0.53% | $1.11M | $4.68B | 11.34% | 73Outperform |
 DT | Dynatrace | 0.51% | $1.05M | $18.51B | 28.25% | 77Outperform |
 BOX | Box | 0.50% | $1.04M | $5.92B | 29.75% | 65Neutral |
 MPC | Marathon Petroleum | 0.47% | $975.05K | $128.40B | 133.32% | 66Neutral |
 HSTM | HealthStream | 0.48% | $1.01M | $1.08B | 32.68% | 69Neutral |
 HAE | Haemonetics | 0.46% | $964.01K | $5.39B | 130.79% | 70Outperform |
 CNK | Cinemark Holdings | 0.46% | $967.32K | $4.60B | 50.00% | 58Neutral |
SIXL Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For SIXL, the sentiment is Positive. The current price of 40.31 is above the 20-day moving average (MA) of 38.63, above the 50-day MA of 39.03, and above the 200-day MA of 38.47, indicating a bullish trend. The MACD of 0.39 indicates Negative momentum. The RSI at 69.18 is Neutral, neither overbought nor oversold. The STOCH value of 92.78 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SIXL.
SIXL Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| SIXL | $40.31 | $42.00(4.20% Upside) | $208.41M | 0.46% | 70Neutral |
 SEUS | $25.88 | $30.96(19.66% Upside) | $945.64M | 0.30% | 73Outperform |
 BGDV | $30.92 | $36.98(19.62% Upside) | $863.22M | 0.45% | 74Outperform |
 AAUB | $50.25 | $60.56(20.51% Upside) | $839.29M | 0.10% | 66Neutral |
 AVTM | $54.22 | $64.68(19.30% Upside) | $775.24M | 0.22% | 60Neutral |
 XCHG | $27.26 | $33.22(21.83% Upside) | $713.00M | 0.50% | 70Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SIXL | ETC 6 Meridian Low Beta Equity ETF | 40.31 | 4.24 | 11.74% | |
| SEUS | SEI QiM U.S. Equity Factor Allocation Active ETF | 25.88 | 0.61 | 2.42% | |
| BGDV | Bahl & Gaynor Dividend ETF | 30.92 | 4.14 | 15.47% | |
| AAUB | Alpha Architect US Equity 4 ETF | 50.25 | 0.77 | 1.55% | |
| AVTM | Avantis Total Equity Markets ETF | 54.22 | 4.58 | 9.22% | |
| XCHG | AB US Equity ETF | 27.26 | 2.42 | 9.72% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.